We recently compiled a list of 8 Cheap Growth Stocks to Buy According to Analysts. In this article, we will look at where ...
Zacks.com on MSN3d
AstraZeneca Stock Up Almost 14% in 6 Months: Time to Buy?AstraZeneca AZN stock has risen 13.6% in the past six months, outperforming an increase of 7.1% for the industry. AstraZeneca ...
The FDA approves AstraZeneca's Tagrisso for treating unresectable, stage III EGFR-mutated non-small cell lung cancer.
The FDA has approved AstraZeneca's Tagrisso for treating unresectable, Stage III EGFR-mutated non-small cell lung cancer, ...
AstraZeneca topped the analyst consensus for net revenue and matched the analyst consensus for core EPS in Q2. See why I ...
智通财经APP获悉，CDE网站显示，阿斯利康(AZN.US)的反义疗法Eplontersen(IONIS-TTR-LRx，商品名：Wainua)在华申报上市，用于治疗遗传性转甲状腺素介导的淀粉样变性多发性神经病(ATTRv-PN)。ATTRv-PN可 ...
Discover top performing closed-end funds with high distributions and discounts in this monthly series for income investors.
The most recent trading session ended with Astrazeneca (AZN) standing at $78.38, reflecting a -0.66% shift from the previouse trading day's closing. The stock's change was less than the S&P 500's ...
British drug major AstraZeneca PLC (AZN, AZN.L) announced Thursday that its Tagrisso (osimertinib) has been approved in the US for ...
05. 阿斯利康(AZN) 2023年收入超过450亿美元，拥有12种重磅药物，并在研发上投资了近110亿美元。公司的研发生产力为19%，高于行业平均水平14%，拥有超过120个处于第二和第三阶段的项目。阿斯利康的战略支柱包括科学与创新、生产力和增长、治疗领域的领导地位，以及人员和可持续性。公司设定了到2030年实现800亿美元收入的目标，并计划在2026年达到中30%的营业利润率。阿斯利康的资本 ...
Check the time stamp on this data. Updated AI-Generated Signals for Astrazeneca Plc (AZN) available here: AZN.
We recently compiled a list of the 10 Best Growth Stocks To Buy According To George Soros. In this article, we will look at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback